A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3Kɑ inhibition in controlling tumor growth.

Posted on February 14, 2020 by

Ruicci KM, Meens J, Sun RX, Rizzo G, Pinto N, Yoo J, Fung K, MacNeil D, Mymryk JS, Barrett JW, Boutros PC, Ailles L, Nichols AC.

Int J Cancer. 2019 Oct 15;145(8):2100-2106. doi: 10.1002/ijc.32009. Epub 2018 Dec 18. Erratum in: Int J Cancer. 2020 Jan 1;146(1):E23.PMID: 30468243

Posted in Manuscript
Back to Publications Return Home
Icons made by Freepik from www.flaticon.com is licensed by CC 3.0 BY